Nikkei edges down on pause in weak yen trend; mining shares outperform
TOKYO, March 30 Japan's Nikkei share average edged down on Thursday morning pressured by a pause in the weak yen trend, while mining shares firmed on gains in oil prices.
Feb 11 Celgene Corp on Monday said its drug Revlimid won full regulatory approval in China for patients with relapsed or refractory multiple myeloma, a type of cancer that starts in the plasma cells in the bone marrow.
Multiple myeloma is the second most commonly diagnosed blood cancer. There are an estimated 750,000 people with the disease worldwide, according to the International Myeloma Foundation.
Celgene said it expects the drug to be available to Chinese patients late in the second quarter of 2013.
In addition, the biotechnology company said Revlimid, or lenalidomide, was granted priority review by the U.S. Food and Drug Administration as a treatment for patients with relapsed or refractory mantle cell lymphoma.
Revlimid is approved in combination with dexamethasone for the treatment of patients with multiple myeloma, who have received at least one prior therapy, in almost 70 countries, including the Americas and Europe.
It is also approved in the United States, Canada, Switzerland, Australia, New Zealand and several Latin American countries, as well as Malaysia and Israel, for transfusion-dependent anemia.
MELBOURNE, March 30 Korea Zinc Inc, the world's third-largest zinc smelter, has agreed to take a 15 percent drop in annual processing fees for 2017 as smelters grapple with a dearth of mine supply, Metal Bulletin reported.